Is Buying Stock Like Collegium Pharmaceutical, Inc. (COLL) After Such Increase Winning Strategy?

April 17, 2018 - By Richard Conner

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Logo

The stock of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) is a huge mover today! The stock increased 6.90% or $1.6 during the last trading session, reaching $24.8. About 424,871 shares traded. Collegium Pharmaceutical, Inc. (NASDAQ:COLL) has risen 133.98% since April 17, 2017 and is uptrending. It has outperformed by 122.43% the S&P500.
The move comes after 7 months positive chart setup for the $819.08M company. It was reported on Apr, 17 by We have $27.03 PT which if reached, will make NASDAQ:COLL worth $73.72 million more.

Analysts await Collegium Pharmaceutical, Inc. (NASDAQ:COLL) to report earnings on May, 9. They expect $-0.62 EPS, up 21.52 % or $0.17 from last year’s $-0.79 per share. After $-0.54 actual EPS reported by Collegium Pharmaceutical, Inc. for the previous quarter, Wall Street now forecasts 14.81 % negative EPS growth.

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Ratings Coverage

Among 3 analysts covering Collegium Pharmaceutical (NASDAQ:COLL), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Collegium Pharmaceutical had 8 analyst reports since October 18, 2017 according to SRatingsIntel. The rating was maintained by Jefferies with “Buy” on Wednesday, October 18. The stock of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) has “Buy” rating given on Wednesday, November 29 by Piper Jaffray. Piper Jaffray maintained it with “Buy” rating and $23.0 target in Thursday, December 14 report. The stock has “Buy” rating by Piper Jaffray on Monday, February 12. The firm earned “Buy” rating on Tuesday, January 23 by Piper Jaffray. Piper Jaffray maintained Collegium Pharmaceutical, Inc. (NASDAQ:COLL) rating on Thursday, December 7. Piper Jaffray has “Buy” rating and $24.0 target. The firm has “Buy” rating by Janney Capital given on Monday, November 6. The company was maintained on Sunday, February 11 by Jefferies.

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. The company has market cap of $819.08 million. It offers Xtampza, an oral formulation of oxycodone, for the management of pain. It currently has negative earnings. The firm also develops Onsolis, a transmucosal immediate-release fentanyl film indicated for the management of breakthrough pain in cancer patients 18 years of age and older.

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.